BioMarin Pharma (BMRN) Tops Q3 EPS by 13c, Revenue Misses
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
BioMarin Announces Third Quarter 2016 Financial Results
October 27, 2016 4:03 PM EDT- Third Quarter 2016 Total BioMarin Revenues Increase 34% Year over Year to $280 million
- Vimizim Net Product Revenues Increase 25% Year over Year to $81 million in the Third Quarter 2016
- Kuvan Net Product Revenues Increase 42% Year over Year to $91 million in the Third Quarter 2016 Â
 Financial Highlights (in millions of U.S. dollars, except per share data, unaudited)
  Three Months Ended September... More